Nisha Pandey

Health and Me

FDA Approves New Treatment Option For Bladder Cancer Unresponsive To Standard Immunotherapy

FDA Approves New Option For Bladder Cancer Unresponsive To Standard Immunotherapy

The US Food and Drug Administration (FDA) recently expanded the approval of Anktiva (nogapendekin alfa inbakicept-pmln), a <a href="https://www.healthandme.com/health/bladder-cancer">bladder cancer</a> treatment, to include adults with high-grade papillary bladder cancer that has not responded to Bacillus Calmette-Guérin (BCG) therapy.

The decision provides a new treatment option for patients whose cancer persists or returns despite standard immunotherapy.

The approval specifically covers BCG-unresponsive, high-grade papillary-only non-muscle-invasive bladder cancer (NMIBC). Anktiva was already approved in April 2024 for certain patients with BCG-unresponsive NMIBC involving carcinoma in situ, with or without papillary tumours.

The latest development is significant because patients with high-grade papillary-only disease previously had fewer approved bladder-preserving treatment options after BCG failed. 

The FDA based its decision on evidence supporting Anktiva's earlier approval, alongside scientific similarities between the two forms of <a href="https://www.healthandme.com/health-wellness/colon-cancer-in-young-adults-the-growing-burden-among-indias-under-50-population-article-156335137" data-type="tilCustomLink">bladder cancer</a>.

“We listen to patients, clinicians, and researchers, and we act when the science supports a new approach,” said R. Angelo de Claro, MD, director of the FDA's Oncology Center of Excellence.

“For Anktiva, our review of the similarities between these cancers allowed us to build on the results in patients with CIS and expand treatment options for people with high-grade papillary tumors alone. This approach may also help guide the development of future treatments.”

<h2>What Is BCG-Unresponsive Bladder Cancer?</h2>

Also read: <a href="https://www.healthandme.com/health-wellness/pope-leo-xivs-lung-cancer-diagnosis-when-should-you-worry-about-lung-nodules-article-156338907" data-type="tilCustomLink">Pope Leo XIV’s Lung Cancer Diagnosis: When Should You Worry About Lung Nodules?</a>

BCG is a form of immunotherapy used to treat high-risk non-muscle-invasive bladder cancer. Although the name comes from a bacterium originally used in tuberculosis vaccination, BCG is administered directly into the bladder to initiate an immune response against cancer cells.

NMIBC refers to bladder cancer that has not grown into the muscle layer of the bladder wall. Treatment often involves removing visible tumours through a procedure called transurethral resection of <a href="https://www.healthandme.com/health-wellness/world-thrombosis-day-can-an-unexplained-blood-clot-be-the-first-sign-of-cancer-experts-explain-article-156329988" data-type="tilCustomLink">bladder tumour</a> (TURBT), followed by BCG therapy to destroy remaining cancer cells and reduce the risk of recurrence.

However, some cancers return despite treatment. These are described as BCG-unresponsive, and patients may need alternative therapies or surgery to remove the bladder.

Also read: <a href="https://www.healthandme.com/health-wellness/could-unusual-antibodies-help-predict-childhood-cancer-years-before-diagnosis-study-gives-clues-article-156340685" data-type="tilCustomLink">Can A Blood Test Predict Childhood Cancer Years Before Diagnosis? Study Gives Clues</a>

Anktiva is an interleukin-15 receptor agonist, a type of immunotherapy designed to strengthen the body's immune response against cancer.

It activates and expands immune cells, including natural killer cells and T cells, which help recognise and attack abnormal cells. When administered with BCG, Anktiva provides an additional immune stimulus to help the body fight cancer within the bladder.

The medicine is delivered directly into the bladder through a catheter, a procedure known as intravesical instillation. This allows treatment to act locally rather than being administered through an intravenous infusion.

Treatment begins with weekly doses for six weeks. Depending on the patient's response, additional induction and maintenance treatment may be given, with the overall treatment period extending up to 37 months.

Dietary Supplements: Hidden Dangers, Fake Claims & How to Choose Safe Protein | Expert Explains

The FDA's original approval was supported by the QUILT-3.032 clinical trial, which included 77 adults with BCG-unresponsive, high-risk NMIBC involving CIS, with or without <a href="https://www.healthandme.com/health-wellness/us-womans-pancreatic-cancer-spotted-on-routine-heart-scan-how-it-saved-her-life-article-156325224" data-type="tilCustomLink">papillary tumours</a>.

The study found a complete response rate of 62%. This means that no high-grade cancer was detected during the relevant assessments. Among patients who achieved a complete response, 58% maintained it for at least 12 months, while 40% maintained it for at least 24 months.

For the expanded approval, the FDA considered these findings alongside laboratory evidence indicating that CIS and high-grade papillary-only tumours share key biological features. Both can recur or progress when BCG treatment fails.

The agency concluded that the earlier evidence of effectiveness could be applied to patients with high-grade papillary-only disease. 

Health Conditions A-Z

health

fda-approves-new-option-for-bladder-cancer-unresponsive-to-standard-immunotherapy

Bladder Cancer

immunotherapy

anktiva

us food and drug administration

nmibc

pope-leo-xiv-resumes-daily-activities-after-lung-cancer-surgery-how-recovery-looks-like-after-lung-lobe-removal

Pope Leo XIV Resumes Daily Activities After Lung Cancer Surgery: How Recovery Looks Like After Lung Lobe Removal

rsv-warning-welsh-mum-urges-pregnant-women-to-get-vaccine-after-baby-nearly-dies

RSV Warning: Welsh Mum Urges Pregnant Women To Get Vaccine After Baby Nearly Dies

Health News

8 Sit-Up Variations to Strengthen Your Core and Build Stability

Benefits Of Ayurvedic Health Supplement Ashwagandha

9 Anti-Inflammatory Breakfast Options You Should Try

5 Foods You Should Avoid For PCOS, Says Gynecologist

Love Sitting With Your Legs Crossed? Here’s You Should Avoid It

6 Daily Foods That Are Secretly Increasing Your Calories

9 Brain Boosters You Should Do Everyday

Hip Exercises That Will Keep You Flexible As You Age

9 Leg Exercises Office Workers’ Should Do At Home

Benefits of Having Herbal Tea Every Morning

9 Daily Habits That Boost Your Brain Power

Lower-Body Exercises That Are Game-Changers

How Drinking Apple Cider Vinegar Helps You

Aging Myths You Should Never Believe

Superfoods That Support Your Gut Health

What Happens To Your Body When You Eat Instant Noodles Every Day?

Health Issues Premature Babies Often Face

Exercises Office Workers Should Do For Their Heart Health

Reasons Why You Should Add Raw Turmeric To Your Diet

Benefits Of Drinking Milk At Night: Why You Should Do It

Food That Provides Vitamin B12 Naturally In Your Diet

Surprising Health Benefits Of Fenugreek Seeds

9 Superfoods You Should Eat For Your Brain Health

What Does Mental Health Support Look Like At Work?

Long Stretches You Should Do To Unwind From Your Day

Colon Cancer In Young Adults: Early Symptoms You Should Know

Health Benefits Of Eating Dry Fruits Everyday

Are You At Risk For Fried Rice Syndrome?

These Tests Reveal How Well You Are Aging

Lower-Back Exercises You Should Do After A Long-Day's Work

Children’s Diet – What Kids Need To Eat For Immunity Building

Common Diabetes Myths That Could Hurt Your Health

Love Spicy Food? Here’s How It Affects Your Health

Superfood List: Veggies And Fruits You Must Have For Immunity

Foods People With IBS Should Avoid

Exercises To Improve Digestion

Easy Work Lunches You Can Make In The Morning

Hunger Vs Craving: Difference Explained In 60 seconds

These Things Can Cause Your Heart To Age Faster

High Carb Foods That Are Actually Healthy

The US Food and Drug Administration (FDA) recently expanded the approval of Anktiva (nogapendekin alfa inbakicept-pmln), a bladder cancer treatment, to include adults with high-grade papillary bladder cancer that has not responded to Bacillus Calmette-Guérin (BCG) therapy. The decision provides a new treatment option for patients whose cancer persists or returns despite standard immunotherapy.The approval specifically covers BCG-unresponsive, high-grade papillary-only non-muscle-invasive bladder cancer (NMIBC). Anktiva was already approved in April 2024 for certain patients with BCG-unresponsive NMIBC involving carcinoma in situ, with or without papillary tumours.The latest development is significant because patients with high-grade papillary-only disease previously had fewer approved bladder-preserving treatment options after BCG failed. The FDA based its decision on evidence supporting Anktiva's earlier approval, alongside scientific similarities between the two forms of bladder cancer.“We listen to patients, clinicians, and researchers, and we act when the science supports a new approach,” said R. Angelo de Claro, MD, director of the FDA's Oncology Center of Excellence.“For Anktiva, our review of the similarities between these cancers allowed us to build on the results in patients with CIS and expand treatment options for people with high-grade papillary tumors alone. This approach may also help guide the development of future treatments.”What Is BCG-Unresponsive Bladder Cancer?Also read: Pope Leo XIV’s Lung Cancer Diagnosis: When Should You Worry About Lung Nodules?BCG is a form of immunotherapy used to treat high-risk non-muscle-invasive bladder cancer. Although the name comes from a bacterium originally used in tuberculosis vaccination, BCG is administered directly into the bladder to initiate an immune response against cancer cells.NMIBC refers to bladder cancer that has not grown into the muscle layer of the bladder wall. Treatment often involves removing visible tumours through a procedure called transurethral resection of bladder tumour (TURBT), followed by BCG therapy to destroy remaining cancer cells and reduce the risk of recurrence.However, some cancers return despite treatment. These are described as BCG-unresponsive, and patients may need alternative therapies or surgery to remove the bladder.More About Anktiva Also read: Can A Blood Test Predict Childhood Cancer Years Before Diagnosis? Study Gives CluesAnktiva is an interleukin-15 receptor agonist, a type of immunotherapy designed to strengthen the body's immune response against cancer.It activates and expands immune cells, including natural killer cells and T cells, which help recognise and attack abnormal cells. When administered with BCG, Anktiva provides an additional immune stimulus to help the body fight cancer within the bladder.The medicine is delivered directly into the bladder through a catheter, a procedure known as intravesical instillation. This allows treatment to act locally rather than being administered through an intravenous infusion.Treatment begins with weekly doses for six weeks. Depending on the patient's response, additional induction and maintenance treatment may be given, with the overall treatment period extending up to 37 months.FDA's Approval For Anktiva    The FDA's original approval was supported by the QUILT-3.032 clinical trial, which included 77 adults with BCG-unresponsive, high-risk NMIBC involving CIS, with or without papillary tumours.The study found a complete response rate of 62%. This means that no high-grade cancer was detected during the relevant assessments. Among patients who achieved a complete response, 58% maintained it for at least 12 months, while 40% maintained it for at least 24 months.For the expanded approval, the FDA considered these findings alongside laboratory evidence indicating that CIS and high-grade papillary-only tumours share key biological features. Both can recur or progress when BCG treatment fails.The agency concluded that the earlier evidence of effectiveness could be applied to patients with high-grade papillary-only disease. 

fda approves new option for bladder cancer unresponsive to standard immunotherapy

About Us

Contact Us

Terms & Conditions

Privacy Policy

Company

Health and Me is a premium website with content written and curated to function as a handbook for all Health concerns.

FDA Approves New Treatment Option For Bladder Cancer Unresponsive To Standard Immunotherapy

Pope Leo XIV Resumes Daily Activities After Lung Cancer Surgery: How Recovery Looks Like After Lung Lobe Removal

US Shelved Poultry Vaccination Due To RFK Jr’s Vaccine Skepticism: Can Vaccine Help Control Bird Flu?

Keralam Senior Citizens Bill: What It Means For India’s Ageing Population

Health Conditions A-Z

Pope Leo XIV Resumes Daily Activities After Lung Cancer Surgery: How Recovery Looks Like After Lung Lobe Removal

FDA Approves New Treatment Option For Bladder Cancer Unresponsive To Standard Immunotherapy

RSV Warning: Welsh Mum Urges Pregnant Women To Get Vaccine After Baby Nearly Dies